Chronic Pruritus Responding to Dupilumab—A Case Series

Abstract

Background: Chronic pruritus is defined as itch lasting for greater than six weeks. Pruritus is a burdensome manifestation of several internal and external disease states with a significant impact on quality of life. Dupilumab has shown promise in treating a number of conditions including atopic dermatitis (AD) and asthma. Its success in reducing pruritus in AD has generated interest regarding its potential application in other pruritic conditions, such as chronic pruritus of unknown origin, uremic pruritus, and pruigo nodularis. Methods: In this retrospective analysis, we present a series of 20 recalcitrant pruritus patients seen at a tertiary center treated with off-label dupilumab at standard AD dosing. Results: Dupilumab was successful at reducing itch in all treated patients, leading to complete resolution in 12/20 patients and an overall mean NRSi reduction of 7.55. Dupilumab was well tolerated with no significant adverse effects. Conclusions: Our case series suggests dupilumab may be a safe and efficacious therapeutic option in several pruritic conditions and demonstrates the need for further studies to better ascertain its place in the pruritus treatment armamentarium.

Efficacy of dupilumab in prurigo nodularis in elderly patient

“…In the literature, some cases of PN were reported that were successfully treated with dupilumab, showing efficacy in reducing the itch (Beck, Yang, Sekhon, Bhutani, & Liao, ; Calugareanu et al, ; Ferrucci, Tavecchio, Berti, & Angileri, ; Mollanazar, Elgash, Weaver, et al, ; Napolitano et al, ; PH1 & JO2, ; Tanis, Ferenczi, & Payette, ; Zhai et al, ).…”

Erfolgreiche Anwendung von Dupilumab bei therapierefraktärer Prurigo nodularis

“…Eine rezente Untersuchung zeigte eine gesteigerte [9]. Im Gegensatz zu unserer Patientin war das subjektive Ansprechen (Reduktion des Pruritus) in den meisten Fällen deutlich früher zu beobachten [10][11][12][13][14]. Nur wenige dieser Patienten zeigten ein langsameres Ansprechen auf die Behandlung mit Dupilumab.…”

Hematologic-Related Malignancy-Induced Eosinophilic Dermatosis (He Remained): An eosinophilic dermatosis predominantly associated with chronic lymphocytic leukemia

“…3,4 The world literature on eosinophilic dermatosis of hematologic malignancy (EDHM) was recently reviewed 5 ; to the best of my knowledge, 206 patients with this condition have been described (Table I). [3][4][5][6][7] EDHM has been observed more frequently in men (55% [107 of 193 patients]) than in women (45% [86 of 193 patients]); sex was not provided for 13 patients.…”